Tumor Necrosis Factor (TNF) can paradoxically increase on etanercept treatment, occasionally contributing to TNF-mediated disease [3]

Journal of Rheumatology

Volumn 34, Issue 2, 2007, Pages 447-449

  Bhatia, Ajay ^a   Kast, Richard E ^b  

^a Ohio State University Harding Hospital   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; OKT 3; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; CASE REPORT; CHROMOSOME 6P; CONGESTIVE HEART FAILURE; ENDOTOXEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE; HUMAN; LETTER; MULTIPLE MYELOMA; PRIORITY JOURNAL; QUALITY OF LIFE; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; HUMANS; IMMUNOGLOBULIN G; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33846953889     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (22)

1. Sari I, Akar S, Birlik M, et al. Anti-tumor necrosis factor-α- induced psoriasis. J Rheumatol 2006;33:1411-4.
2. Hochberg MC, Lebwohl MG, Plevy SE. The benefit/risk profile of TNF-blocking agents: Findings of a consensus panel. Semin Arthritis Rheum 2005;34:819-36.
3. Kupper TS. Immunologic targets in psoriasis. New Engl J Med 2003;349:1987-90.
4. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized controlled trial. Ann Intern Med 1999;130:478-86.
5. Keystone EC, Schiff MH, Kremer JM, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis - results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50:353-63.
6. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis -a randomized controlled trial. Lancet 2000;356:385-90.
7. Lebwohl MG. Advances in psoriasis. Arch Dermatol 2005;141:1589-90.
8. Schon MP, Boehnke WH. Psoriasis. N Engl J Med 2005;352:1899-912.
9. Tsimberidou AM, Waddelow T, Kantarjian HM, Albitar M, Giles FJ. Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment. Leuk Res 2003;27:375-80.
10. Suffredini AF, Reda D, Banks SM, et al. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J Immunol 1995;155:5038-45.
11. Zou JX, Braun J, Sieper J. Immunological basis for the use of TNF-alpha blocking agents in ankylosing spondylitis and immunological changes during treatment. Clin Exp Rheumatol 2002;20 Suppl:S34-7.
12. Zou J, Rudwaleit M, Brandt J, et al. Up-regulation of the production of TNF-alpha and IFN-gamma by T cells in ankylosing spondylitis during treatment with etanercept. Ann Rheum Dis 2003;62:561-4.
13. Madhusudan S, Foster M, Muthuramalingam SR, et al. A phase II study of etanercept (Enbrel), a TNF-alpha inhibitor in patients with metastatic breast cancer. Clin Cancer Res 2004;10:6528-34.
14. Nowlan ML, Drewe E, Bulsara H, et al. Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A. Rheumatology Oxford 2006;45:31-7.
15. Eason JD, Pascual M, Wee S, et al. Evaluation of recombinant human soluble dimeric tumor necrosis factor receptor for prevention of OKT3-associated acute clinical syndrome. Transplantation 1996;61:224-8.
16. Kast RE. Evidence of a mechanism by which etanercept increased TNF-alpha in multiple myeloma: New insights into the biology of TNF-alpha giving new treatment opportunities - the role of bupropion. Leukemia Res 2005;29:1459-63.
17. Cianci R, Cammarota G, Raducci F, et al. The impact of biological agents interfering with receptor/ligand binding in the immune system. Eur Rev Med Phamacol Sci 2005;9:305-14.
18. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001;121:1088-94.
19. Oh J, Arkfield DG, Horwitz DA. Development of Crohn's disease in a patient taking etanercept. J Rheumatol 2005;32:752-3.
20. Ruemmele FM, Prieur AM, Talbotec C, et al. Development of Crohn's disease during anti-TNF-alpha therapy in a child with juvenile idiopathic arthritis. J Pediatr Gastroenterol Nutr 2004;39:203-6.
21. Anker SD, Coates AJ. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWEL, and ATTACH. Int J Cardiol 2002;86: 123-30.
22. Kwon HJ, Cote TR, Cuffe MS, et al. Case reports of heart failure after therapy with tumor necrosis factor antagonist. Ann Intern Med 2003;138:807-11.